Mylan Scores PTAB Review Of Teva’s Copaxone Patents
Teva's three-times-a-week Copaxone has been key to its franchise protection; now that defense could quickly come under generic threat as well.
Teva's three-times-a-week Copaxone has been key to its franchise protection; now that defense could quickly come under generic threat as well.